While we are not aware of any other study that has provided a head-to-head comparison of plasma and PET imaging ATN biomarkers in relation to the presence of amyloid pathology and the severity of cognitive impairment across the AD spectrum, several design limitations should be acknowledged. The gene discussed is TYR; the disease is Cognitive impairment.